Author

J.-B. Gorin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Organism:human· 2 Assay:proteomics· 2 Approach:benchmark study· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

J. K. Sandberg· 2 shared S. Aleman· 2 shared A. Olsson· 1 shared A. Perez-Potti· 1 shared A. Sonnerborg· 1 shared B. Strunz· 1 shared D. A. Price· 1 shared D. F. G. Malone· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J. K. Sandberg

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

T. Sekine, A. Perez-Potti, O. Rivera-Ballesteros, K. Straling, J.-B. Gorin, A. Olsson, S. Llewellyn-Lacey, H. Kamal, G. Bogdanovic, S. Muschiol, D. J. Wulliman, T. Kammann, J. Emgard, T. Parrot, E. Folkesson, , Karolinska COVID-19 Study Group

The paper maps SARS-CoV-2-specific T cell responses in individuals with asymptomatic/mild COVID-19 and finds robust memory T cell responses similar to vaccines, detectable even in antibody-seronegative individuals.

bioRxiv · Jun 29, 2020Immunology

Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection

J.-B. Gorin, D. F. G. Malone, B. Strunz, T. Carlsson, S. Aleman, N. K. Björkström, K. Falconer, J. K. Sandberg

This study examines how plasma inflammatory markers change during DAA therapy for CHC, finding that FABP4 levels correlate with liver disease improvement.

bioRxiv · Dec 24, 2019Immunology